We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Chronic Myeloid Leukaemia

The pre-treatment transcript level of t(9;22) [BCR-ABL] can inform prognosis and determine downstream log reduction levels.

In addition, three monthly follow up MRD analysis is recommended as per national and international guidelines.

Studies have indicated PB monitoring for most follow up time-points is sufficient, with BM monitoring at stipulated time points, according to national and ELN guidelines, where these will help to inform when cytogenetics testing is necessary.

The use of donor lymphocyte infusion (DLI) can be indicated in post-transplant patients. Therefore if DLI is being used, a clinically urgent test request can be made, so that a shorter turnaround time is implemented in the laboratory to support therapeutic decision making. This would also be available when other clinical urgencies require this, such as loss of a response or disease progression.


(Last reviewed 12th February 2018)